| __timestamp | Alkermes plc | Incyte Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 447875000 | 3004000 |
| Thursday, January 1, 2015 | 483393000 | 26972000 |
| Friday, January 1, 2016 | 519270000 | 58187000 |
| Sunday, January 1, 2017 | 567637000 | 79479000 |
| Monday, January 1, 2018 | 601826000 | 94123000 |
| Tuesday, January 1, 2019 | 693218000 | 114249000 |
| Wednesday, January 1, 2020 | 572904000 | 131328000 |
| Friday, January 1, 2021 | 603913000 | 150991000 |
| Saturday, January 1, 2022 | 218108000 | 206997000 |
| Sunday, January 1, 2023 | 253037000 | 255000000 |
| Monday, January 1, 2024 | 245331000 | 312068000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biopharmaceuticals, cost management is crucial. From 2014 to 2023, Alkermes plc and Incyte Corporation have shown contrasting trends in their cost of revenue. Alkermes, with a peak in 2019, saw a 55% increase from 2014, reaching its highest cost of revenue. However, by 2022, it plummeted by 68%, reflecting strategic shifts or market challenges. Incyte, on the other hand, demonstrated a steady climb, with a staggering 8,400% increase from 2014 to 2023, indicating robust growth and possibly expanding operations. The year 2023 marked a pivotal moment as Incyte's cost of revenue surpassed Alkermes for the first time, suggesting a shift in market dynamics. This data not only highlights the financial strategies of these companies but also offers insights into the evolving biopharma industry landscape.
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Incyte Corporation
Cost Insights: Breaking Down Teva Pharmaceutical Industries Limited and Alkermes plc's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Incyte Corporation or Alkermes plc: Who Leads in Yearly Revenue?
Cost Insights: Breaking Down Incyte Corporation and ACADIA Pharmaceuticals Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Dyne Therapeutics, Inc.
Incyte Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Bio-Techne Corporation and Alkermes plc
Analyzing Cost of Revenue: Jazz Pharmaceuticals plc and Alkermes plc
Analyzing Cost of Revenue: Pharming Group N.V. and Alkermes plc
Cost of Revenue: Key Insights for Alkermes plc and Ligand Pharmaceuticals Incorporated
Cost of Revenue Comparison: Alkermes plc vs Mesoblast Limited